Abstract
Objectives: Liver function is a key component of efavirenz metabolism and might be altered in severe liver fibrosis induced by HIV/chronic hepatitis co-infection. However, data evaluating the impact of liver fibrosis stages on the plasma efavirenz level are lacking. Patients and methods: In this study, conducted in 134 HIV-infected patients [77, 35 and 22 HIV mono-infected, HIV/hepatitis C virus (HCV) co-infected and HIV/hepatitis B virus (HBV) co-infected, respectively] treated with efavirenz 600 mg once a day in combination with other antiretroviral agents, plasma concentration was measured at least 8 h after the last drug intake using a validated HPLC method. The degree of liver fibrosis was determined by means of either liver biopsy or non-invasive biochemical markers (Fibrotest®). The proportions of patients above a threshold of 4000 ng/mL were compared by means of Pearson's χ2 test or Fisher's exact test. Results: In HIV mono-infected and HIV/HCV and HIV/HBV co-infected patients, mean ± SD efavirenz plasma concentrations were 3060 ± 1928, 4108 ± 3324 and 3163 ± 2432 ng/mL, respectively. The proportion of patients with an efavirenz concentration above 4000 ng/mL differed significantly according to the presence of hepatitis and the fibrosis stage. A concentration above 4000 ng/mL was found in 14 patients (18.2%) mono-infected with HIV compared with 5 (22.7%, P = 0.01) and 9 (25.7%, P = 0.001) HIV/HBV or HIV/HCV co-infected patients, respectively. When the fibrosis stage was considered in all patients with hepatitis, 3 cirrhotic patients (42.6%) had an efavirenz concentration above the 4000 ng/mL threshold [compared with 14 (18.2%) HIV mono-infected patients, P = 0.001]. Conclusions: Therapeutic drug monitoring may be of interest in cirrhotic patients more at risk of side effects due to efavirenz overdosing. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Author supplied keywords
Cite
CITATION STYLE
Meynard, J. L., Lacombe, K., Poirier, J. M., Legrand, J., Morand-Joubert, L., & Girard, P. M. (2009). Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. Journal of Antimicrobial Chemotherapy, 63(3), 579–584. https://doi.org/10.1093/jac/dkn531
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.